Terms: = Lung cancer AND CCND2, KIAK0002, 894, ENSG00000118971, P30279, MGC102758 AND Treatment
51 results:
1. 5-Hydroxymethylcytosine in Cell-Free DNA Predicts Immunotherapy Response in lung cancer.
Shao J; Xu Y; Olsen RJ; Kasparian S; Sun K; Mathur S; Zhang J; He C; Chen SH; Bernicker EH; Li Z
Cells; 2024 Apr; 13(8):. PubMed ID: 38667328
[TBL] [Abstract] [Full Text] [Related]
2. Multi-classification model incorporating radiomics and clinic-radiological features for predicting invasiveness and differentiation of pulmonary adenocarcinoma nodules.
Sun H; Zhang C; Ouyang A; Dai Z; Song P; Yao J
Biomed Eng Online; 2023 Nov; 22(1):112. PubMed ID: 38037082
[TBL] [Abstract] [Full Text] [Related]
3. Using Radiomics to Differentiate Brain Metastases From lung cancer Versus Breast cancer, Including Predicting Epidermal Growth Factor Receptor and human Epidermal Growth Factor Receptor 2 Status.
Shi J; Chen H; Wang X; Cao R; Chen Y; Cheng Y; Pang Z; Huang C
J Comput Assist Tomogr; 2023 Nov-Dec 01; 47(6):924-933. PubMed ID: 37948368
[TBL] [Abstract] [Full Text] [Related]
4. Progression before local control in osteosarcoma: Outcome and prognosis-predictive factors.
Halalsheh H; Amer S; Sultan I
Pediatr Blood Cancer; 2023 Nov; 70(11):e30649. PubMed ID: 37638816
[TBL] [Abstract] [Full Text] [Related]
5. Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland.
Barbier MC; Fengler A; Pardo E; Bhadhuri A; Meier N; Gautschi O
Pharmacoeconomics; 2023 Dec; 41(12):1641-1655. PubMed ID: 37572261
[TBL] [Abstract] [Full Text] [Related]
6. Clinical effect of surgical treatment for lung metastasis and prognostic risk factor analysis: a single-centred cohort study.
Peng D; Sun W
ANZ J Surg; 2023 Jun; 93(6):1551-1558. PubMed ID: 37226585
[TBL] [Abstract] [Full Text] [Related]
7. A strategy to reduce the false-positive rate after low-dose computed tomography in lung cancer screening: A multicenter prospective cohort study.
Wu Z; Tan F; Xie Y; Tang W; Wang F; Xu Y; Cao W; Qin C; Dong X; Zheng Y; Luo Z; Wang C; Zhao L; Xia C; Li J; Li R; Feng F; Li J; Ren J; Shi J; Cui H; Shen S; Wu N; Chen W; Li N; He J
Cancer Med; 2023 Jul; 12(13):14781-14793. PubMed ID: 37199391
[TBL] [Abstract] [Full Text] [Related]
8. Assessment of bone-targeting agents use in patients with bone metastasis from breast, lung or prostate cancer using structured and unstructured electronic health records from a regional UK-based hospital.
Seesaghur A; Egger P; Warden J; Abbasi A; Levick B; Riaz M; McMahon P; Thompson M; Cheeseman S
BMJ Open; 2023 May; 13(5):e069214. PubMed ID: 37156580
[TBL] [Abstract] [Full Text] [Related]
9. A contrast-enhanced MRI-based nomogram to identify lung metastasis in soft-tissue sarcoma: A multi-centre study.
Hu Y; Wang H; Yue Z; Wang X; Wang Y; Luo Y; Jiang W
Med Phys; 2023 May; 50(5):2961-2970. PubMed ID: 36433749
[TBL] [Abstract] [Full Text] [Related]
10. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell lung cancer: The ASTRUM-005 Randomized Clinical Trial.
Cheng Y; Han L; Wu L; Chen J; Sun H; Wen G; Ji Y; Dvorkin M; Shi J; Pan Z; Shi J; Wang X; Bai Y; Melkadze T; Pan Y; Min X; Viguro M; Li X; Zhao Y; Yang J; Makharadze T; Arkania E; Kang W; Wang Q; Zhu J;
JAMA; 2022 Sep; 328(12):1223-1232. PubMed ID: 36166026
[TBL] [Abstract] [Full Text] [Related]
11. Identification and therapeutic evaluation of ALK rearrangements in non-small-cell lung cancer.
Zhao R; Guo L; Zhang B; Zhao J; Xiang C; Chen S; Shao J; Zhu L; Ye M; Han Y
J Pathol Clin Res; 2022 Nov; 8(6):538-549. PubMed ID: 35848751
[TBL] [Abstract] [Full Text] [Related]
12. A Novel Prognostic Signature Revealed the Interaction of Immune Cells in Tumor Microenvironment Based on Single-Cell RNA Sequencing for lung Adenocarcinoma.
Jin X; Hu Z; Sui Q; Zhao M; Liang J; Liao Z; Zheng Y; Wang H; Shi Y
J Immunol Res; 2022; 2022():6555810. PubMed ID: 35812244
[TBL] [Abstract] [Full Text] [Related]
13. BAP18 induces growth of non-small-cell lung carcinoma through upregulating transcriptional level of CCND1/2.
Wei SJ; Li J; Wang JY; Zhang LX; Zhang HB; Du DJ; Li QX
Eur Rev Med Pharmacol Sci; 2022 May; 26(9):3074-3082. PubMed ID: 35587057
[TBL] [Abstract] [Full Text] [Related]
14. Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System.
Wu B; Shen P; Yin X; Yu L; Wu F; Chen C; Li J; Xu T
Br J Clin Pharmacol; 2023 Feb; 89(2):440-448. PubMed ID: 35349180
[TBL] [Abstract] [Full Text] [Related]
15. Optimizing the radiomics-machine-learning model based on non-contrast enhanced CT for the simplified risk categorization of thymic epithelial tumors: A large cohort retrospective study.
Feng XL; Wang SZ; Chen HH; Huang YX; Xin YK; Zhang T; Cheng DL; Mao L; Li XL; Liu CX; Hu YC; Wang W; Cui GB; Nan HY
Lung Cancer; 2022 Apr; 166():150-160. PubMed ID: 35287067
[TBL] [Abstract] [Full Text] [Related]
16. miR-466 Contributes to the Enhanced Antitumor Effect of Bortezomib on Non-Small-Cell lung cancer by Inhibiting CCND1.
Wang WH; Zhan JM; Tang YL; Zhou N; Liu WY; Jiang DW
Chemotherapy; 2022; 67(2):110-122. PubMed ID: 35042223
[TBL] [Abstract] [Full Text] [Related]
17. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial.
Naccache JM; Jouneau S; Didier M; Borie R; Cachanado M; Bourdin A; Reynaud-Gaubert M; Bonniaud P; Israël-Biet D; Prévot G; Hirschi S; Lebargy F; Marchand-Adam S; Bautin N; Traclet J; Gomez E; Leroy S; Gagnadoux F; Rivière F; Bergot E; Gondouin A; Blanchard E; Parrot A; Blanc FX; Chabrol A; Dominique S; Gibelin A; Tazi A; Berard L; Brillet PY; Debray MP; Rousseau A; Kerjouan M; Freynet O; Dombret MC; Gamez AS; Nieves A; Beltramo G; Pastré J; Le Borgne-Krams A; Dégot T; Launois C; Plantier L; Wémeau-Stervinou L; Cadranel J; Chenivesse C; Valeyre D; Crestani B; Cottin V; Simon T; Nunes H;
Lancet Respir Med; 2022 Jan; 10(1):26-34. PubMed ID: 34506761
[TBL] [Abstract] [Full Text] [Related]
18. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract] [Full Text] [Related]
19. Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for lung adenocarcinoma.
Gao L; Zhang L
BMC Cancer; 2021 Jul; 21(1):849. PubMed ID: 34301211
[TBL] [Abstract] [Full Text] [Related]
20. Concurrent Chemoradiation Therapy With or Without Nimotuzumab in Locally Advanced Squamous Cell lung cancer: A Phase 2 Randomized Trial.
Qiu B; Wang D; Li Q; Wu Y; Guo S; Jiang X; Fang J; Guo J; Liu F; Chu C; Wang B; Chen L; Zhang J; Liu Y; Hu Y; Liu H
Int J Radiat Oncol Biol Phys; 2021 Nov; 111(4):917-925. PubMed ID: 34229051
[TBL] [Abstract] [Full Text] [Related]
[Next]
